UK-based company Genomics has entered a collaborative deal with US-based biotechnology firm Biogen to discover new treatments for multiple sclerosis (MS).
Researchers from the Universities of Exeter and Alberta have identified a protein in the brain which they believe could be key in the onset of multiple sclerosis.